Table 2 CCL20 and CCR6-related inhibitors

1

GSK3050002

Aggregates containing complement proteins can serve as substrates for complement activation

Humanized IgG1κ monoclonal antibody targeting CCL20

[128]

2

Di-S-IdoA

Humanized IgG1κ monoclonal antibody targeting CCL20

Small-molecule carbohydrates

[30]

3

NCT01984047

Neutralization of monoclonal antibodies (mAbs) with the chemokine ligand CCL20

A humanized anti-CCL20 monoclonal antibody (mAb)

[129]

4

CCX9664

Targeting CCR6 reduces T lymphocyte infiltration

A small-molecule antagonist of CCR6

[124]

5

Infliximab

TNF-induced upregulation of CCL20 is inhibited by the NF-κB pathway

Monoclonal antibody

[4, 123]

6

etanercept

Anti-TNF-α modified fusion protein

Monoclonal antibody

[4, 123]

7

Tocilizumab

Block CD4⁺ T lymphocyte differentiation into Th17 cells

Antibodies targeting the interleukin-6 receptor (IL-6R) production

[4, 123]

8

CO339589

Inhibition of CCL20-mediated chemotaxis and binding in human natural killer (NK) cells and CCR6-rich peripheral blood mononuclear cells (PBMCs)

A small-molecule antagonist effective against CCR6 in both humans and mice

[4]

9

WO2017011559A1

Competitive inhibition of CCR6 binding to CCL20

Anti-CCL20 antibody

[130]

10

IDOR-1117–2520

Migration of CCR6 to the bronchus and alveoli is inhibited

A highly effective small-molecule antagonist of CCR6

[127]

11

PF-07054894

Blocking CCR6-mediated chemotaxis and the binding of CCL20 to CCR6

A selective small-molecule antagonist of CCR6

[126]